| Literature DB >> 25998151 |
Gang Liu1, Chao Liu2, Xue-Ning Zhang3.
Abstract
The present study aimed to examine the neurophysiological mechanisms of the 2,6-diisopropylphenol and N-methyl-D-aspartate (NMDA) receptor antagonist against learning and memory impairment, induced by electroconvulsive therapy (ECT). A total of 48 adult depressed rats without olfactory bulbs were randomly divided into six experimental groups: i) saline; ii) 10 mg/kg MK‑801; iii) 10 mg/kg MK‑801 and a course of ECT; iv) 200 mg/kg 2,6‑diisopropylphenol; v) 200 mg/kg 2,6‑diisopropylphenol and a course of ECT; and vi) saline and a course of ECT. The learning and memory abilities of the rats were assessed using a Morris water maze 1 day after a course of ECT. The hippocampus was removed 1 day after assessment using the Morris water maze assessment. The content of glutamate in the hippocampus was detected using high‑performance liquid chromatography. The expression levels of p‑AT8Ser202 and GSK‑3β1H8 in the hippocampus were determined using immunohistochemical staining and western blot analysis. The results demonstrated that the 2,6‑diisopropylphenol NMDA receptor antagonist, MK‑801 and ECT induced learning and memory impairment in the depressed rats. The glutamate content was significantly upregulated by ECT, reduced by 2,6‑diisopropylphenol, and was unaffected by the NMDA receptor antagonist in the hippocampus of the depressed rats. Tau protein hyperphosphorylation in the hippocampus was upregulated by ECT, but was reduced by 2,6‑diisopropylphenol and the MK‑801 NMDA receptor antagonist. It was also demonstrated that 2,6‑diisopropylphenol prevented learning and memory impairment and reduced the hyperphosphorylation of the Tau protein, which was induced by eECT. GSK‑3β was found to be the key protein involved in this signaling pathway. The ECT reduced the learning and memory impairment, caused by hyperphosphorylation of the Tau protein, in the depressed rats by upregulating the glutamate content.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25998151 PMCID: PMC4526078 DOI: 10.3892/mmr.2015.3803
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Morris water maze assessment of escape latency.
| Group | Saline | NMDA receptor antagonist | 2,6-diisopropylphenol | Total | F-statistic | P-value |
|---|---|---|---|---|---|---|
| Control | 26.65±3.39 | 36.35±3.30 | 34.59±3.91 | 32.53±5.48 | 17.009 | 0.000 |
| ECT | 61.68±8.26 | 45.77±5.53 | 43.93±4.34 | 50.46±10.10 | 19.425 | 0.000 |
| Total | 44.17±19.09 | 41.06±6.56 | 39.26±6.26 | 41.49±12.11 | 3.809 | 0.030 |
| F-statistic | 123.107 | 17.102 | 20.463 | 148.986 | – | – |
| P-value | 0.000 | 0.001 | 0.000 | 0.000 | – | – |
Data are expressed as the mean ± standard deviation (n=8). Crossover effect, F=32.870 and P<0.001;
F-statistic and P-value of main effect; ECT, electroconvulsive therapy.
Morris water maze assessment of space probe duration.
| Group | Saline | NMDA receptor antagonist | 2,6-diisopropylphenol | Total | F-statistic | P-value |
|---|---|---|---|---|---|---|
| Control | 26.36±4.21 | 11.17±1.69 | 11.86±1.51 | 16.46±7.62 | 77.237 | 0.000 |
| ECT | 10.92±2.30 | 16.38±2.16 | 17.67±1.65 | 14.99±3.58 | 24.363 | 0.000 |
| Total | 18.64±8.61 | 13.78±3.28 | 14.76±3.37 | 15.73±5.94 | 17.863 | 0.000 |
| F-statistic | 82.814 | 28.928 | 54.291 | 4.376 | – | – |
| P-value | 0.000 | 0.000 | 0.000 | 0.043 | – | – |
Data are expressed as the mean ± standard deviation (n=8). Crossover effect, F=98.938 and P<0.001;
F-statistic and P-value of main effect; ECT, electroconvulsive therapy.
Glu content in the rat hippocampus (µmol/gprot).
| Group | Saline | NMDA receptor antagonist | 2,6-diisopropylphenol | Total | F-statistic | P-value |
|---|---|---|---|---|---|---|
| Control | 46.51±9.35 | 49.43±9.77 | 36.90±6.25 | 44.28±9.87 | 4.652 | 0.021 |
| ECT | 162.16±31.89 | 149.93±24.86 | 92.32±16.34 | 134.80±39.32 | 17.553 | 0.000 |
| Total | 104.34±63.89 | 70.88±25.69 | 64.61±31.02 | 89.54±53.82 | 21.320 | 0.000 |
| F-statistic | 96.903 | 113.283 | 80.278 | 277.841 | – | – |
| P-value | 0.000 | 0.000 | 0.000 | 0.000 | – | – |
Data are expressed as the mean ± standard deviation (n=8). Crossover effect, F=11.091 and P<0.001;
F-statistic and P-value of main effect; ECT, electroconvulsive therapy.
Figure 1Representative images of the expression levels of (A) p-AT8Ser202 and (B) GSK-3β1H8 in the hippocampus of rats (magnification, ×400; n=8). (C) Protein expression levels of p-AT8Ser202 and GSK-3β1H8 in the hippocampal tissues of depressed rats without olfactory bulbs. I. i.p injection of 5 ml saline; II, i.p injection of 5 ml 10 mg/kg NMDA receptor antagonist (MK-801); III, i.p injection of 5 ml 10 mg/kg NMDA receptor antagonist (MK-801) and a course of ECT; IV, i.p injection of 5 ml 200 mg/kg 2,6-diisopropylphenol; V, i.p injection of 5 ml 200 mg/kg 2,6-diisopropylphenol and a course of ECT; VI, i.p injection of 5 ml saline and a course of ECT. ECT, electroconvulsive therapy.
Number of p-AT8Ser202 IR-positive cells the in rat hippocampus.
| Group | Saline (n) | NMDA receptor antagonist (n) | 2,6-diisopropylphenol (n) | Total (n) | F-statistic | P-value |
|---|---|---|---|---|---|---|
| Control | 39.13±6.94 | 21.50±3.59 | 20.25±2.76 | 26.96±9.92 | 38.964 | 0.000 |
| ECT | 80.13±11.63 | 48.88±6.77 | 53.13±8.48 | 60.71±16.64 | 27.257 | 0.000 |
| Total | 59.63±23.11 | 35.19±15.07 | 36.69±18.04 | 43.83±21.78 | 56.003 | 0.000 |
| F-statistic | 73.329 | 102.138 | 108.781 | 255.037 | – | – |
| P-value | 0.000 | 0.000 | 0.000 | 0.000 | – | – |
Data are expressed as the mean ± standard deviation (n=8). Crossover effect, F=3.507 and P=0.039;
F-statistic and P-value of main effect; ECT, electroconvulsive therapy.
Integral absorbance value of positive cells in rat hippocampus (p-AT8Ser202-IR).
| Group | Saline | MDA receptor antagonist | 2,6-diisopropylphenol | Total | F-statistic | P-value |
|---|---|---|---|---|---|---|
| Control | 0.1807±0.0135 | 0.0727±0.0119 | 0.0644±0.0114 | 0.1060±0.0554 | 222.375 | 0.000 |
| ECT | 0.4095±0.0521 | 0.1585±0.0200 | 0.1634±0.0125 | 0.2438±0.1238 | 150.951 | 0.000 |
| Total | 0.2951±0.1238 | 0.1156±0.0471 | 0.1139±0.0524 | 0.1749±0.1177 | 279.136 | 0.000 |
| F-statistic | 144.283 | 108.566 | 273.455 | 366.698 | – | – |
| P-value | 0.000 | 0.000 | 0.000 | 0.000 | – | – |
Data are expressed as the mean ± standard deviation (n=8). Crossover effect, F=40.174 and P<0.001;
F-statistic and P-value of main effect; ECT, electroconvulsive therapy.
Integral absorbance value of positive cells in rat hippocampus (GSK-3β1H8-IR).
| Group | Saline | NMDA receptor antagonist | 2,6-diisopropylphenol | Total | F-statistic | P-value |
|---|---|---|---|---|---|---|
| Control | 0.1012±0.1169 | 0.0645±0.0043 | 0.0634±0.0063 | 0.0815±0.0267 | 106.291 | 0.000 |
| ECT | 0.1673±0.0132 | 0.0873±0.0072 | 0.0899±0.0062 | 0.1148±0.0389 | 187.156 | 0.000 |
| Total | 0.1421±0.0288 | 0.0758±0.0132 | 0.0767±0.0150 | 0.0982±0.0371 | 291.269 | 0.000 |
| F-statistic | 62.186 | 60.189 | 71.389 | 167.764 | – | – |
| P-value | 0.000 | 0.000 | 0.000 | 0.000 | – | – |
Data are expressed as the mean ± standard deviation (n=8). Crossover effect, F=11.247 and P<0.001;
F-statistic and P-value of main effect; ECT, electroconvulsive therapy.
Western blot analysis and integral absorbance value of p-AT8Ser199/202 protein content in rat hippocampus.
| Group | Saline | NMDA receptor antagonist | 2,6-diisopropylphenol | Total | F-statistic | P-value |
|---|---|---|---|---|---|---|
| Control | 695.38±151.65 | 405.25±74.39 | 399.88±89.92 | 500.17±176.16 | 23.879 | 0.000 |
| ECT | 1354.38±94.42 | 913.13±76.87 | 888.13±71.15 | 1051.88±232.17 | 50.175 | 0.000 |
| Total | 1024.88±361.52 | 659.19±272.26 | 644.00±264.02 | 776.02±345.37 | 73.129 | 0.000 |
| F-statistic | 119.457 | 101.646 | 149.425 | 350.725 | – | – |
| P-value | 0.000 | 0.000 | 0.000 | 0.000 | – | – |
Data are expressed as the mean ± standard deviation (n=8). Crossover effect, F=4.580 and P=0.016;
F-statistic and P-value of main effect; ECT, electroconvulsive therapy.
Western blot analysis and integral absorbance value of GSK-3β1H8 protein content in rat hippocampus.
| Group | Saline | NMDA receptor antagonist | 2,6-diisopropylphenol | Total | F-statistic | P-value |
|---|---|---|---|---|---|---|
| Control | 496.75±98.35 | 327.25±62.21 | 329.75±52.06 | 384.58±107.29 | 13.937 | 0.000 |
| ECT | 700.75±52.42 | 400.13±61.09 | 392.75±58.00 | 497.88±156.46 | 75.294 | 0.000 |
| Total | 598.75±129.98 | 363.69±70.45 | 361.25±62.39 | 441.23±144.53 | 68.465 | 0.000 |
| F-statistic | 26.806 | 5.589 | 5.227 | 35.412 | – | – |
| P-value | 0.000 | 0.033 | 0.038 | 0.000 | – | – |
Data are expressed as the mean ± standard deviation (n=8). Crossover effect, F=5.698 and P=0.006;
F-statistic and P-value of main effect; ECT, electroconvulsive therapy.
Quantity of positive cells in rat hippocampus (GSK-3β1H8-IR).
| Group | Saline | NMDA receptor antagonist | 2,6-diisopropylphenol | Total | F-statistic | P-value |
|---|---|---|---|---|---|---|
| Control | 35.88±7.04 | 15.25±3.06 | 14.38±2.97 | 21.83±11.12 | 52.452 | 0.000 |
| ECT | 65.25±13.47 | 32.75±6.06 | 31.13±6.62 | 43.04±18.37 | 33.947 | 0.000 |
| Total | 50.56±18.38 | 24.00±10.16 | 22.75±9.97 | 32.44±18.45 | 71.848 | 0.000 |
| F-statistic | 29.895 | 53.096 | 42.607 | 98.216 | – | – |
| P-value | 0.000 | 0.000 | 0.000 | 0.000 | – | – |
Data are expressed as the mean ± standard deviation (n=8). Crossover effect, F=3.651 and P=0.035;
F-statistic and P-value of main effect; ECT, electroconvulsive therapy.